Cargando…
Associations of Renin‐Angiotensin System Antagonist Medication Adherence and Economic Outcomes Among Commercially Insured US Adults: A Retrospective Cohort Study
BACKGROUND: Medication non‐adherence can result in considerable morbidity, mortality, and costs. The Pharmacy Quality Alliance hypertension medication adherence measure is used by US healthcare payers and providers to assess renin‐angiotensin system antagonist medication adherence. However, associat...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660763/ https://www.ncbi.nlm.nih.gov/pubmed/32844732 http://dx.doi.org/10.1161/JAHA.119.016094 |
_version_ | 1783609076050034688 |
---|---|
author | Campbell, Patrick J. Axon, David R. Taylor, Ann M. Pickering, Matthew Black, Heather Warholak, Terri Chinthammit, Chanadda |
author_facet | Campbell, Patrick J. Axon, David R. Taylor, Ann M. Pickering, Matthew Black, Heather Warholak, Terri Chinthammit, Chanadda |
author_sort | Campbell, Patrick J. |
collection | PubMed |
description | BACKGROUND: Medication non‐adherence can result in considerable morbidity, mortality, and costs. The Pharmacy Quality Alliance hypertension medication adherence measure is used by US healthcare payers and providers to assess renin‐angiotensin system antagonist medication adherence. However, associations between renin‐angiotensin system antagonist adherence as calculated in quality measures, and healthcare service use and expenditure in commercial populations over a 1‐year timeframe has not been assessed. METHODS AND RESULTS: This retrospective cohort study used eligible commercially insured individuals from the Truven Health MarketScan Commercial Claims and Encounters Research Databases (2009–2015). Generalized linear models with log link and gamma distribution (expenditure) or negative binomial distribution (usage) assessed relationships between hypertension adherence (≥80% proportion of days covered) and healthcare use and expenditures (in 2015 US dollars) while adjusting for covariates (age, sex, geographic region; health plan; Deyo‐Charlson Comorbidity Index, number of chronic medications, and treatment naivety). Beta coefficients were used to compute cost ratios and rate ratios. A total of 4 842 058 subjects were eligible; of those, 3 310 360 (68%) were adherent (adherent mean age 53.3±8.0 years, 55.9% men; non‐adherent mean age 50.3±9.1 years, 53.1% men). Adherence was associated with fewer inpatient (rate ratios, 0.612; 95% CI, 0.607–0.617) and outpatient visits (rate ratios, 0.995; 95% CI, 0.994–0.997); and lower total costs (cost ratios, 0.876; 95% CI, 0.874–0.878) compared with non‐adherence. Adherence was associated with lower average per member per month total costs ($97.98) compared with non‐adherence. CONCLUSIONS: Adherence to renin‐angiotensin system antagonists was associated with fewer outpatient and inpatient visits, and lower total costs compared with non‐adherence in a 1‐year time frame. |
format | Online Article Text |
id | pubmed-7660763 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-76607632020-11-17 Associations of Renin‐Angiotensin System Antagonist Medication Adherence and Economic Outcomes Among Commercially Insured US Adults: A Retrospective Cohort Study Campbell, Patrick J. Axon, David R. Taylor, Ann M. Pickering, Matthew Black, Heather Warholak, Terri Chinthammit, Chanadda J Am Heart Assoc Original Research BACKGROUND: Medication non‐adherence can result in considerable morbidity, mortality, and costs. The Pharmacy Quality Alliance hypertension medication adherence measure is used by US healthcare payers and providers to assess renin‐angiotensin system antagonist medication adherence. However, associations between renin‐angiotensin system antagonist adherence as calculated in quality measures, and healthcare service use and expenditure in commercial populations over a 1‐year timeframe has not been assessed. METHODS AND RESULTS: This retrospective cohort study used eligible commercially insured individuals from the Truven Health MarketScan Commercial Claims and Encounters Research Databases (2009–2015). Generalized linear models with log link and gamma distribution (expenditure) or negative binomial distribution (usage) assessed relationships between hypertension adherence (≥80% proportion of days covered) and healthcare use and expenditures (in 2015 US dollars) while adjusting for covariates (age, sex, geographic region; health plan; Deyo‐Charlson Comorbidity Index, number of chronic medications, and treatment naivety). Beta coefficients were used to compute cost ratios and rate ratios. A total of 4 842 058 subjects were eligible; of those, 3 310 360 (68%) were adherent (adherent mean age 53.3±8.0 years, 55.9% men; non‐adherent mean age 50.3±9.1 years, 53.1% men). Adherence was associated with fewer inpatient (rate ratios, 0.612; 95% CI, 0.607–0.617) and outpatient visits (rate ratios, 0.995; 95% CI, 0.994–0.997); and lower total costs (cost ratios, 0.876; 95% CI, 0.874–0.878) compared with non‐adherence. Adherence was associated with lower average per member per month total costs ($97.98) compared with non‐adherence. CONCLUSIONS: Adherence to renin‐angiotensin system antagonists was associated with fewer outpatient and inpatient visits, and lower total costs compared with non‐adherence in a 1‐year time frame. John Wiley and Sons Inc. 2020-08-26 /pmc/articles/PMC7660763/ /pubmed/32844732 http://dx.doi.org/10.1161/JAHA.119.016094 Text en © 2020 The Authors, Merck Sharp Inc. and Dohme Corp Inc. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Research Campbell, Patrick J. Axon, David R. Taylor, Ann M. Pickering, Matthew Black, Heather Warholak, Terri Chinthammit, Chanadda Associations of Renin‐Angiotensin System Antagonist Medication Adherence and Economic Outcomes Among Commercially Insured US Adults: A Retrospective Cohort Study |
title | Associations of Renin‐Angiotensin System Antagonist Medication Adherence and Economic Outcomes Among Commercially Insured US Adults: A Retrospective Cohort Study |
title_full | Associations of Renin‐Angiotensin System Antagonist Medication Adherence and Economic Outcomes Among Commercially Insured US Adults: A Retrospective Cohort Study |
title_fullStr | Associations of Renin‐Angiotensin System Antagonist Medication Adherence and Economic Outcomes Among Commercially Insured US Adults: A Retrospective Cohort Study |
title_full_unstemmed | Associations of Renin‐Angiotensin System Antagonist Medication Adherence and Economic Outcomes Among Commercially Insured US Adults: A Retrospective Cohort Study |
title_short | Associations of Renin‐Angiotensin System Antagonist Medication Adherence and Economic Outcomes Among Commercially Insured US Adults: A Retrospective Cohort Study |
title_sort | associations of renin‐angiotensin system antagonist medication adherence and economic outcomes among commercially insured us adults: a retrospective cohort study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660763/ https://www.ncbi.nlm.nih.gov/pubmed/32844732 http://dx.doi.org/10.1161/JAHA.119.016094 |
work_keys_str_mv | AT campbellpatrickj associationsofreninangiotensinsystemantagonistmedicationadherenceandeconomicoutcomesamongcommerciallyinsuredusadultsaretrospectivecohortstudy AT axondavidr associationsofreninangiotensinsystemantagonistmedicationadherenceandeconomicoutcomesamongcommerciallyinsuredusadultsaretrospectivecohortstudy AT taylorannm associationsofreninangiotensinsystemantagonistmedicationadherenceandeconomicoutcomesamongcommerciallyinsuredusadultsaretrospectivecohortstudy AT pickeringmatthew associationsofreninangiotensinsystemantagonistmedicationadherenceandeconomicoutcomesamongcommerciallyinsuredusadultsaretrospectivecohortstudy AT blackheather associationsofreninangiotensinsystemantagonistmedicationadherenceandeconomicoutcomesamongcommerciallyinsuredusadultsaretrospectivecohortstudy AT warholakterri associationsofreninangiotensinsystemantagonistmedicationadherenceandeconomicoutcomesamongcommerciallyinsuredusadultsaretrospectivecohortstudy AT chinthammitchanadda associationsofreninangiotensinsystemantagonistmedicationadherenceandeconomicoutcomesamongcommerciallyinsuredusadultsaretrospectivecohortstudy |